Genetic variability in CYP3A5 and its possible consequences

被引:242
作者
Xie, HG
Wood, AJJ
Kim, RB
Stein, CM
Wilkinson, GR
机构
[1] Vanderbilt Univ, Sch Med, Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Pharmacol, Div Clin Pharmacol, Nashville, TN 37232 USA
关键词
CYP3A4; CYP3A5; ethnic diversity; molecular genetic; epidemiology; pharmacogenetics; pharmacogenomics polymorph ism; population genetics;
D O I
10.1517/phgs.5.3.243.29833
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The cytochrome P450 3A (CYP3A) subfamily members are the most abundant and important drug-metabolizing enzymes in humans, and wide interindividual variability in CYP3A expression and function is present. CYP3A4 alone cannot fully explain the observed constitutive variability because its genetic variants are relatively uncommon and have limited functional significance, whereas CYP3A5 expression in humans is highly variable and may be contributory. However, it is difficult to delineate the relative contribution of CYP3A4 and CYP3A5, and to differentiate their effects on drug metabolism as their protein structure, function and substrates are so similar. By contrast, molecular biology methods provide the ability to identify CYP3A4 and CYP3A5 genotypes with certainty. This review collates currently available data on CYP3A5 polymorphisms, provides information on the population frequency of each genetic variant in major ethnic groups, and describes in vitro and in vivo studies that have attempted to identify genotype-phenotype associations.
引用
收藏
页码:243 / 272
页数:30
相关论文
共 164 条
[41]   The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module [J].
Goodwin, B ;
Hodgson, E ;
Liddle, C .
MOLECULAR PHARMACOLOGY, 1999, 56 (06) :1329-1339
[42]   Regulation of CYP3A gene transcription by the pregnane X receptor [J].
Goodwin, B ;
Redinbo, MR ;
Kliewer, SA .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2002, 42 :1-+
[43]  
GORSKI JC, 1994, BIOCHEM PHARMACOL, V47, P1643
[44]   Cancer statistics, 2000 [J].
Greenlee, RT ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (01) :7-33
[45]   Cytochrome P-450 3A4: Regulation and role in drug metabolism [J].
Guengrich, FP .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :1-17
[46]  
Haehner BD, 1996, MOL PHARMACOL, V50, P52
[47]   Genetics - FDA races in wrong direction [J].
Haga, SB ;
Venter, JC .
SCIENCE, 2003, 301 (5632) :466-466
[48]   GENE STRUCTURE OF CYP3A4, AN ADULT-SPECIFIC FORM OF CYTOCHROME-P450 IN HUMAN LIVERS, AND ITS TRANSCRIPTIONAL CONTROL [J].
HASHIMOTO, H ;
TOIDE, K ;
KITAMURA, R ;
FUJITA, M ;
TAGAWA, S ;
ITOH, S ;
KAMATAKI, T .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1993, 218 (02) :585-595
[49]   The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients [J].
Haufroid, V ;
Mourad, M ;
Van Kerckhove, V ;
Wawrzyniak, J ;
De Meyer, M ;
Eddour, DC ;
Malaise, J ;
Lison, D ;
Squifflet, JP ;
Wallemacq, P .
PHARMACOGENETICS, 2004, 14 (03) :147-154
[50]   A perfect message: RNA surveillance and nonsense-mediated decay [J].
Hentze, MW ;
Kulozik, AE .
CELL, 1999, 96 (03) :307-310